NCT02390752

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2015-04-29Est. Completion: 2026-12-31

Enrollment target: 54 participants

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Contact

NCI POB Solid Tumor Referral Teamncipobstreferrals@mail.nih.gov (240) 858-7012

Rosandra N Kaplan, M.D.kaplanrn@mail.nih.gov (240) 760-6198

Other microbiome trials you might be interested in

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)Phase 1Recruiting

Adipocytic NeoplasmLiposarcomaAtypical FibroxanthomaAngiomatoid Fibrous HistiocytomaMyoepitheliomaFibrosarcoma NOSMyxofibrosarcomaAngiosarcomaOsteosarcoma, Extraskeletal

The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To…

Atlanta, United StatesEst. completion Jun 2034

View Trial →

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)Recruiting

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.